Sale of Pegzilarginase to Immedica (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Jul. 27, 2023 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
|
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
| Proceeds from sale of in-process research and development asset | $ 30,000 | $ 0 | ||
| Gain on sale of in-process research and development asset | 30,000 | $ 0 | ||
| Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights to Pegzilarginase | ||||
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
| Proceeds from sale of in-process research and development asset | $ 15,000 | |||
| Contingent consideration | $ 100,000 | |||
| Gain on sale of in-process research and development asset | 30,000 | |||
| Receivable outstanding | $ 3,000 | $ 3,000 | ||